Corpus Intelligence IC Memo — AUXILIO MUTUO HOSPITAL 2026-04-26 05:22 UTC
IC Memo — AUXILIO MUTUO HOSPITAL
Investment Committee Memorandum | PR | 481 beds | Grade C | EBITDA uplift $17.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

AUXILIO MUTUO HOSPITAL

CCN 400016 | nan, PR | 481 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

AUXILIO MUTUO HOSPITAL is a 481-bed suburban community hospital in nan, PR with $232.1M in net patient revenue and a -1.7% operating margin. The hospital serves a payer mix of 9.9% Medicare, 11.9% Medicaid, and 78.2% commercial.

Thesis: Undervalued. Our ML models identify $17.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -1.7% to 5.7% (+736bps).

Net Revenue HCRIS$232.1M
Current EBITDA COMPUTED$-3.9M
Operating Margin COMPUTED-1.7%
Occupancy HCRIS63.8%
Revenue / Bed COMPUTED$483K
Net-to-Gross HCRIS52.0%
Distress Probability ML50.9%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
947
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -1.7% places it above the state median. Among 947 size-comparable peers (240-962 beds), the median margin is -3.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (240-962), prioritizing same-state peers. 947 hospitals in the comp set.

HospitalStateBedsRevenueMargin
AUXILIO MUTUO HOSPITAL (Target)PR481$232.1M-1.7%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
CEDARS-SINAI MEDICAL CENTERCA908$3.92B-5.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $17.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.9M+210bp18mo
Cost to Collect4.5%2.5%$4.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.8M+122bp9mo
Clean Claim Rate88.0%96.0%$149K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.9M
Cost to Collect
$4.6M
Denial Rate Reduction
$4.6M
A/R Days Reduction
$2.8M
Clean Claim Rate
$149K
Total EBITDA Uplift$17.1M
Current EBITDA$-3.9M
+ RCM Uplift+$17.1M
Pro Forma EBITDA$13.2M
Current Margin-1.7%
Pro Forma Margin5.7%
WC Released (1x)$8.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-6.0M$145.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-6.0M$157.7M0.00x-100.0%
Bull Case9.0x11.0x$-5.4M$212.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-5.4M$229.9M0.00x-100.0%
Bear Case11.0x10.0x$-6.6M$61.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-6.6M$65.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 947 hospitals with 240-962 beds
  • Same-state prioritization (n=6)
  • Comp margins: P25=-13.6% / P50=-3.8% / P75=4.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.